Skip to content

Variable Frequency Stimulation of Subthalamic Nucleus for Freezing of Gait in Parkinson's Disease

Double-Blind Trial of Variable Frequency Stimulation for Freezing of Gait in Parkinson's Disease

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02601144
Enrollment
28
Registered
2015-11-10
Start date
2015-10-31
Completion date
2016-12-31
Last updated
2017-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Keywords

DBS, VFS, FOG

Brief summary

This is the first study on the effect of the variable frequency stimulation (VFS) on Freezing of gait (FOG) in Parkinson's disease (PD) patients with STN DBS. FOG has responded poorly to High frequency stimulation (HFS) but can be alleviated by relatively VFS. This study would have significant clinical implications in the management of Freezing of gait (FOG) in these PD patients with subthalamic nucleus (STN) DBS. The investigators hypothesize that VFS could have better effect on FOG than HFS and low frequency stimulation (LFS).

Detailed description

HFS of STN provides consistent, long-term improvement of the cardinal motor signs of PD, such as bradykinesia, tremor and rigidity. FOG has responded poorly to HFS and tends to continue to deteriorate over time, but this can be alleviated by relatively LFS. Evidence has indicated that LFS-STN can improve axial signs in some but not all PD patients, but most of them experienced loss of efficacy in the short term. Then comes to the little improvement or even worse of tremor, rigidity and bradykinesia, which consists of the three main symptoms of Parkinson's disease. Thus even if axial problems could be solved by LFS in a long way, it could also be hard to tolerate by those patients. The effect of VFS on FOG will be studied. The investigators hypothesize that VFS could have better effect on Freezing of gait than HFS and LFS.

Interventions

DEVICEDeep Brain Stimulation

Deep Brain Stimulation

Sponsors

Beijing Pins Medical Co., Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients were receiving bilateral STN stimulation for more than six months. 2. They were optimized on conventional HFS for control of tremors, rigidity and bradykinesia yet complained of freezing of gait. 3. Subjects had an ability to walk at least 10 meters independently during ON DBS condition.

Exclusion criteria

1. gait disorders perceived by patients as a direct consequence of STN stimulation and not the primary disease. 2. any change in the HFS DBS settings, three months prior to participation in the study. 3. complete inability to walk despite assistance while DBS ON. 4. Subjects responding to reprogramming of chronic DBS settings (report improvement of freezing). 5. Subjects could not tolerate prolonged OFF medication condition.

Design outcomes

Primary

MeasureTime frameDescription
Timed Up and Go (TUG) taskThe outcome of TUG task at 12 months follow-up.variable frequency stimulation (VFS) setting compared to high frequency stimulation (HFS) and low frequency stimulation (LFS)
the number of freezing episodes for TUG taskThe outcome of TUG task at 12 months follow-up.variable frequency stimulation (VFS) setting compared to high frequency stimulation (HFS) and low frequency stimulation (LFS)

Secondary

MeasureTime frame
the39-item Parkinson's Disease Questionnaire (PDQ-39) scoresOutcome of VFS at 6、12 months with reference to baseline HFS
UPDRS III scoresOutcome of VFS at 6、12 months with reference to baseline HFS
Number of adverse events (AE's)Change from Baseline to 6、12 Months
the Freezing of Gait Questionnaire (FOG-Q) scoresOutcome of VFS at 6 、12months with reference to baseline HFS
Gait and Falls Questionnaire (GFQ) scoresOutcome of VFS at 6、12 months with reference to baseline HFS

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026